Efficacy vs. IA Corticosteroid

shoe image
For osteoarthritis knee pain

Superior pain relief versus intra-articular (IA) corticosteroid

A 3-injection cycle of HYALGAN®* provided significantly better pain relief than a 3-injection cycle of an intra-articular corticosteroid (6-MPA) at 60 days (P<.05)14,36

Superior pain relief versus intra-articular (IA) corticosteroid line graph

Adapted from Leardini, et al.

Study design

Open-label, parallel, randomized, controlled trial (N=40) comparing HYALGAN® 20 mg/wk X 3 with 6-methylprednisolone acetate (steroid) 40 mg/wk X 3.14

Following treatment with HYALGAN®
  • Patients experienced pain relief that persisted or improved at days 35 and 60

*Some patients may experience benefit with 3 HYALGAN® injections given at weekly intervals. This has been noted in studies of patients receiving 3 injections who were followed for 60 days10

6-MPA=6-methylprednisolone acetate.

‡ Mean spontaneous pain score during normal daily living activities recorded on a 100-mm VAS.

Important Safety Information for HYALGAN®

  • HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
  • HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
  • The effectiveness of a single treatment cycle of less than 3 injections has not been established
  • In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
  • Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
  • In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

Click here for additional important information for HYALGAN®.